ImmuCell Corporation (ICCC): Price and Financial Metrics


ImmuCell Corporation (ICCC): $8.34

-0.01 (-0.12%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ICCC to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ICCC Stock Summary

  • Immucell Corp's market capitalization of $72,928,359 is ahead of only 12.19% of US-listed equities.
  • With a price/earnings ratio of 2,003.31, Immucell Corp P/E ratio is greater than that of about 99.6% of stocks in our set with positive earnings.
  • Price to trailing twelve month operating cash flow for ICCC is currently 139.57, higher than 96.81% of US stocks with positive operating cash flow.
  • Stocks that are quantitatively similar to ICCC, based on their financial statements, market capitalization, and price volatility, are SRDX, NXGN, TSEM, SRI, and CSBR.
  • ICCC's SEC filings can be seen here. And to visit Immucell Corp's official web site, go to immucell.com.

ICCC Valuation Summary

  • In comparison to the median Healthcare stock, ICCC's price/earnings ratio is 547.67% lower, now standing at -163.4.
  • ICCC's EV/EBIT ratio has moved down 172.5 over the prior 243 months.
  • Over the past 243 months, ICCC's price/sales ratio has gone up 3.4.

Below are key valuation metrics over time for ICCC.

Stock Date P/S P/B P/E EV/EBIT
ICCC 2021-08-31 4.4 2.2 -163.4 -164.0
ICCC 2021-08-30 4.3 2.2 -161.3 -161.9
ICCC 2021-08-27 4.2 2.1 -156.9 -157.4
ICCC 2021-08-26 4.3 2.2 -160.6 -161.2
ICCC 2021-08-25 4.2 2.1 -154.8 -155.3
ICCC 2021-08-24 4.1 2.0 -152.3 -152.8

ICCC Growth Metrics

    The 3 year price growth rate now stands at -7.32%.
  • Its 4 year revenue growth rate is now at 40.63%.
  • Its 3 year net income to common stockholders growth rate is now at -264.84%.
ICCC's revenue has moved up $6,556,178 over the prior 33 months.

The table below shows ICCC's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 17.54247 0.522525 0.036404
2021-06-30 16.11482 -0.403793 -0.434248
2021-03-31 14.53896 -0.165421 -1.341154
2020-12-31 15.3422 1.315578 -1.022117
2020-09-30 15.23075 1.112708 -1.521399
2020-06-30 14.47873 1.713629 -1.701046

ICCC Price Target

For more insight on analysts targets of ICCC, see our ICCC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $14.00 Average Broker Recommendation 1.5 (Moderate Buy)

ICCC Stock Price Chart Interactive Chart >

Price chart for ICCC

ICCC Price/Volume Stats

Current price $8.34 52-week high $10.96
Prev. close $8.35 52-week low $7.30
Day low $8.16 Volume 1,700
Day high $8.35 Avg. volume 11,557
50-day MA $9.05 Dividend yield N/A
200-day MA $8.88 Market Cap 64.58M

ImmuCell Corporation (ICCC) Company Bio


ImmuCell Corporation, an animal health company, acquires, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was founded in 1982 and is headquartered in Portland, Maine.


ICCC Latest News Stream


Event/Time News Detail
Loading, please wait...

ICCC Latest Social Stream


Loading social stream, please wait...

View Full ICCC Social Stream

Latest ICCC News From Around the Web

Below are the latest news stories about Immucell Corp that investors may wish to consider to help them evaluate ICCC as an investment opportunity.

ImmuCell (NASDAQ:ICCC) Has A Somewhat Strained Balance Sheet

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

Yahoo | February 26, 2022

ImmuCell Corp (ICCC) CEO Michael Brigham Q4 2021 Results Earnings Call Transcript

No summary available.

Seeking Alpha | February 23, 2022

ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2021

Annual Product Sales for 2021 Increased 25% over 2020PORTLAND, Maine, Feb. 22, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter and year ended December 31, 2021. Product Sales Results: During the three-month p

Yahoo | February 22, 2022

ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2021

Conference Call Scheduled for Wednesday, February 23, 2022 at 9:00 AM ETPORTLAND, Maine, Feb. 16, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter and year ended December 31, 2021 after the market closes on Tues

Yahoo | February 16, 2022

ImmuCell Announces Record Preliminary, Unaudited Sales Results for the Year Ended December 31, 2021

PORTLAND, Maine, Jan. 05, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the year ended December 31, 2021. Preliminary, Unaudited Total Sales Results: 2021 2020 $ Increase % IncreaseDuring the Quarters Ended Decemb

Yahoo | January 5, 2022

Read More 'ICCC' Stories Here

ICCC Price Returns

1-mo -14.90%
3-mo 1.21%
6-mo -7.33%
1-year -14.64%
3-year 35.39%
5-year 34.95%
YTD 4.25%
2021 34.46%
2020 15.53%
2019 -26.95%
2018 -19.80%
2017 47.73%

Continue Researching ICCC

Want to see what other sources are saying about Immucell Corp's financials and stock price? Try the links below:

Immucell Corp (ICCC) Stock Price | Nasdaq
Immucell Corp (ICCC) Stock Quote, History and News - Yahoo Finance
Immucell Corp (ICCC) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8476 seconds.